AIDS Alert Archives – March 1, 2010
March 1, 2010
View Issues
-
Graying plague: By 2015 over half of HIV in U.S. will be in those over 50
Contrary to stereotypes, HIV in America is showing more than a touch of gray. -
Rapid aging, frailty common in older HIV
Frailty is not a diagnosis that typically comes to mind when clinicians examine HIV patients, but with increasing numbers of older people being diagnosed or younger patients growing old with the disease, it should be on HIV clinicians' radar. -
Research takes close look at HIV's impact on brain of aging patients
Research consistently has shown that HIV-positive patients perform cognitively at lower levels than their uninfected peers, an expert says. -
Expert tips for treating older HIV patients
AIDS-defining conditions and risks are different for HIV-positive patients who are older, usually defined as age 50 and above, experts say. -
Perinatal HIV: Decline, but disparities persist
Although the total number of annual perinatal HIV infections in the United States has decreased approximately 90% since 1991 and continue to fall in the most recent data set from 2004-2007 racial/ethnic disparities persist, the Centers for Disease Control and Prevention reports. -
'Persistent stigmas' fueling HIV in black community
"We have a national responsibility to alleviate the HIV/AIDS-related suffering of African-Americans by ensuring that they have full knowledge ofand access toall proven forms of HIV prevention, treatment and care," Anthony S. Fauci, MD, director, National Institute of Allergy and Infectious Diseases said Feb. 7, 2010, commemorating the 10th annual National Black HIV/AIDS Awareness Day. -
PROMISE targets maternal transmission
An estimated 430,000 children worldwide became infected with HIV in 2008, mostly through birth or breastfeeding from an HIV-infected mother. -
FDA Notifications
On Jan. 29, 2009, the Food and Drug Administration (FDA) approved revisions to the lopinavir/ritonavir (Kaletra®) package insert to include drug-drug interaction information for concurrent lopinavir/ritonavir administration with inhaled medicines such as salmeterol or salmeterol in combination with fluticasone propionate (Serevent®, Advair®) and sildenafil (Revatio®).